What the research shows

In a 26-week phase 2 trial, researchers compared several cagrilintide groups with placebo and an active comparator in adults with overweight or obesity who did not have diabetes. Assuming participants stayed on treatment, estimated average weight change in the highest cagrilintide group was −10.8%, compared with −3.0% on placebo. These are group averages over the trial period. Read the randomized cagrilintide trial.

The REDEFINE 1 trial record identifies separate groups receiving the combination, cagrilintide, semaglutide or placebo. The arm name matters when attributing a result to a single compound. Read the REDEFINE 1 trial record.

Documented formats

The phase 2 study used a subcutaneous cagrilintide preparation. The REDEFINE 1 record separately identifies the combination preparation. Keep the product name and study arm together when comparing them.

Testing and purity

Check for cagrilintide’s identity and its chemical modifications. In a combination, an assay for one active ingredient leaves the identity and amount of the second ingredient unresolved.

How to read a batch report

Questions about Cagrilintide

Are cagrilintide and CagriSema the same study material?

CagriSema refers to the combination with semaglutide. Look for the cagrilintide-only arm to understand evidence about the single ingredient.

Is a trial average the result for each participant?

Individual changes vary. The average summarizes outcomes under the study’s enrollment, follow-up and analysis rules.